CPNE1 promotes stemness and confers resistance to GPC3 CAR-T cell therapy in hepatocellular carcinoma via the STAT3-TGF-β signaling pathway.
Silencing one gene restores CAR-T cell function against liver cancer and strengthens immune infiltration without systemic toxicity.
CPNE1 overexpression in HCC drives T-cell exhaustion via STAT3-TGF-β signaling; CPNE1 knockdown restores GPC3-targeted CAR-T cell function, enhances intratumoral T-cell infiltration, and improves antitumor efficacy without systemic toxicity; high CPNE1 correlates with poor ICI outcomes clinically. This record was retained from the prior triage attempt for PubMed pipeline handoff.
What the study was
- Study design
- experimental (mechanistic, in vitro + in vivo)
- Category
- novel_therapeutics
- Maturity
- Exploratory
- Journal
- J Immunother Cancer
Why it surfaced
Directly addresses CAR-T resistance in HCC—a major barrier to solid tumor CAR-T therapy; J Immunother Cancer (premier immunotherapy journal); integrative mechanistic + clinical correlate; CPNE1 is a novel, actionable resistance node distinct from known mechanisms.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.